Dr. Bever is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1650 Orleans St
Rm 186
Baltimore, MD 21287Phone+1 410-955-8893Fax+1 410-367-2194
Education & Training
Johns Hopkins UniversityFellowship, Medical Oncology, 2016 - 2018
University of Maryland School of MedicineClass of 2011
Certifications & Licensure
MD State Medical License 2015 - 2026
NC State Medical License 2020 - 2022
PA State Medical License 2020 - 2022
OK State Medical License 2020 - 2021
MA State Medical License 2014 - 2016- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Phosphodiesterase-5 inhibition collaborates with vaccine-based immunotherapy to reprogram myeloid cells in pancreatic ductal adenocarcinoma.Nicole E Gross, Zhehao Zhang, Jacob T Mitchell, Soren Charmsaz, Alexei G Hernandez
JCI Insight. 2024-08-06 - 1 citationsGemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer.H Catherine Wilbur, Jennifer N Durham, Su Jin Lim, Katrina Purtell, Katherine M Bever
Cancer Research Communications. 2023-08-01 - 7 citationsSociety for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer.Ronan J Kelly, Katherine Bever, Joseph Chao, Kristen K Ciombor, Cathy Eng
Journal for Immunotherapy of Cancer. 2023-06-01
Press Mentions
Novel Treatment Shows Early Promise for Gastric CancerJanuary 26th, 2022- Behind the Study: Metformin and Rapamycin as Maintenance TherapyDecember 13th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
